Detalhe da pesquisa
1.
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Cell
; 185(3): 563-575.e11, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35120664
2.
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
Br J Cancer
; 124(7): 1214-1221, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33473164
3.
Treatment of Advanced Prostate Cancer.
Annu Rev Med
; 70: 479-499, 2019 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30691365
4.
Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center Experience.
J Natl Compr Canc Netw
; 18(12): 1623-1630, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33285516
5.
The landscape of immunotherapy in metastatic urothelial carcinoma.
Curr Opin Urol
; 29(6): 643-648, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31567441
6.
Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC).
Br J Cancer
; 119(9): 1041-1043, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30344307
7.
Correction: Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
Br J Cancer
; 126(8): 1236, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35145255
8.
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
JCO Precis Oncol
; 8: e2300274, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691813
9.
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI.
Cancer Imaging
; 23(1): 110, 2023 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37964386
10.
Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma.
Cancers (Basel)
; 15(11)2023 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37296940
11.
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Clin Cancer Res
; 29(22): 4586-4595, 2023 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37682528
12.
Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients.
Clin Genitourin Cancer
; 20(1): 69-79, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903480
13.
Genomic heterogeneity as a barrier to precision oncology in urothelial cancer.
Cell Rep
; 41(12): 111859, 2022 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36543146
14.
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.
Clin Genitourin Cancer
; 20(5): 431-441, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35676169
15.
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.
JCO Precis Oncol
; 6: e2100392, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731998
16.
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
J Clin Oncol
; 40(12): 1312-1322, 2022 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35089812
17.
FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation.
Nat Commun
; 13(1): 6575, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36323682
18.
NECTIN4 Heterogeneity and Molecular Diversity in Bladder Cancers: Deconstructing the Activity of An Antibody-Drug Conjugate.
Clin Cancer Res
; 27(18): 4950-4952, 2021 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34281911
19.
Pretreatment Eosinophil Counts in Patients With Advanced or Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1 Checkpoint Inhibitors.
J Immunother
; 44(7): 248-253, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34081050
20.
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract.
Cancer Med
; 10(3): 1074-1083, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33382520